证券代码：002438 证券简称：江苏神通 江苏神通阀门股份有限公司投资者关系活动记录表 编号：2025-024 | | □特定对象调研 | □分析师会议 | | --- | --- | --- | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □√其他（电话调研） | | | 参与单位名称及 | | 信达证券、中信建投证券自营、中信资管、六妙星私募、诺安基 | | 人员姓名 | 金、申万菱信基金 | | | 时间 | 2025 年 12 月 23 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 副总裁、董事会秘书：章其强先生 | | | 员姓名 | 投资者关系经理：张健先生 | | | 投资者关系活动 | | 机构投资者就公司生产经营情况、未来发展规划和战略等进行沟 | | 主要内容介绍 | 通交流。 | | | 附件清单（如有） | 具体内容详见附件：2025 年 12 月 | 23 日投资者调研会议记录 | | 日期 | 2025 年 12 月 23 日 | | ...

证券代码： 002540 证券简称：亚太科技 债券代码： 127082 债券简称：亚科转债 江苏亚太轻合金科技股份有限公司投资者关系活动记录表 编号：2025-投 008 在热管理系统领域，公司产品主要包含：汽车座舱系统热管 理铝材，如空调液冷管、复合管、无缝管、微通道管及流量控制 阀材料、膨胀阀、储液罐、热泵材料等；汽车动力系统热管理铝 材，如冷凝器液冷管、圆柱电池液冷管、方形电池口琴管、流量 控制阀、膨胀阀、连接件材料等，致力于满足汽车各类型热管理 系统尤其是液冷系统对高散热效率、低渗漏、高耐压、高密封、 长寿命、轻量化材料的要求。凭借在热管理领域材料开发及应用 方面的深厚沉淀，除汽车热管理外，公司还持续助力家用商用空 调、储能温控、数据中心等工业热管理领域对更高散热性能、更 小型轻量化、更优成本结构的升级迭代需求。 四、在航空航天领域，公司产品主要包括哪些？ 答： 公司航空航天领域产品主要为飞机液压、制动、密封、热交 换、舱门、座椅等系统用高强度铝合金材。航空航天是公司近年 积极部署和拓展的重要领域，通过航空质量管理体系规范建设、 国家行业标准制定参与、新型材料产品开发等工作的持续进行， 公司已获得中国 ...

证券代码：000811 证券简称：冰轮环境 冰轮环境技术股份有限公司投资者关系活动记录表 编号：【2025】第 095 号 | 投资者关 | □特定对象调研 | □分析师会议 | | --- | --- | --- | | | □媒体采访 | □业绩说明会 | | 系 | □新闻发布会 | √路演活动 | | 活动类别 | □现场参观 | □其他 | | 参与单位 | | | | 名称 | | 光大证券陈佳宁、梅玲、王礼沫、华夏基金吕佳玮、王嘉伟、吴昊 | | 及人员姓 | | | | 名 | | | | 时间 | 2025 年 12 月 24 日 | | | 地点 | 公司会议室 | | | 上市公司 | | | | 接 | 董事会秘书孙秀欣 | | | 待人员姓 | | | | 名 | | | 活动期间谈论的主要内容如下： 一、讨论了业务情况和产业板块 公司致力于在能源和动力领域提供先进的系统解决方案和全生 命周期服务，主要产品形式为压缩机和换热装置，实施温控、增压等 冷热能管理功能，覆盖-271℃-200℃温度区间。具体有螺杆式压缩机、 离心式压缩机、吸收式制冷机、活塞式压缩机、涡旋式压缩机、工业 热泵 ...

Group 1: Automotive Business Overview - The company focuses on the research, production, and sales of high-strength precision fasteners and special connectors, primarily used in automotive engine turbocharging systems, transmission control systems, exhaust systems, and key components of electric vehicles [2] - The automotive business has seen steady revenue growth, driven by the expansion of overseas markets and new customer development, including partnerships with major clients like NIO and BYD [9][10] - The gross margin of the automotive business has declined due to factors such as rising material costs and increased depreciation from new projects, but profitability is expected to improve in 2026 [11] Group 2: Commercial Aerospace Business Overview - The commercial aerospace sector is expanding, with the company manufacturing rocket structural components, including body segments and fuel tanks, and has completed production line construction in 2024 [3] - The company has a production capacity of 10 rockets per year and is building a second production line to meet increasing demand [3] - Structural components account for approximately 25% of the cost of a commercial rocket, indicating significant market potential [3] Group 3: Market Dynamics and Competitive Landscape - The commercial aerospace industry is experiencing a supply-demand imbalance, with limited suppliers capable of large-scale delivery, particularly in key regions [3] - The company has established stable relationships with leading private rocket companies, enhancing its competitive edge through experienced personnel and resource advantages [3][4] - The demand for rocket structural components is expected to grow, driven by increased launch frequency and the maturation of reusable rocket technology [6][7] Group 4: Future Outlook and Strategic Initiatives - The company is actively expanding its customer base in the commercial aerospace sector and anticipates new clients entering into bulk cooperation by Q1 2026 [5][6] - The development of reusable rocket technology is expected to enhance launch frequency and operational efficiency, creating new business opportunities for the company [7] - The company is conducting feasibility studies for fuel tank production lines, aiming to align with market trends and customer needs [8]

Group 1: Core Competitiveness - The company's core competitiveness lies in its strong R&D capabilities and deep technical accumulation, focusing on in-depth research of storage media and continuous accumulation of testing cases [1] - The company has consistently driven growth through technological upgrades, enhancing its importance and influence in the storage industry chain [1] - The company develops proprietary storage control and firmware solutions, combined with supply chain management and quality control systems, to innovate and launch competitive storage solutions [1] Group 2: Market Dynamics - The rise in storage prices is expected to temporarily increase costs for downstream consumer electronics, but long-term demand for both consumer electronics and storage products will continue to grow due to technological innovation [1] - The industry is currently experiencing limited capacity increases due to the time lag in production capacity construction, despite a surge in data storage demand driven by AI [2] Group 3: Role in the Industry - Storage module manufacturers play a crucial role in the storage industry by providing flexible storage solutions and supply chain management, meeting the customized needs of downstream clients [3] - As the capabilities of storage solutions expand and overall scale increases, the importance and influence of storage module manufacturers in the industry chain will continue to rise [3] Group 4: Price Trends - Data storage demand driven by AI continues to impact storage prices, with major cloud service providers placing large orders, leading to supply shortages in non-server markets [4] - The CFM flash memory market is expected to maintain an upward trend in Q1 2026, with price increases projected: Mobile eMMC/UFS by 25%-30%, LPDDR4X/5X by 30%-35%, and PC DDR5/LPDDR5X by 30%-35% [4]

Group 1: Company Overview - The company focuses on high-barrier generic drugs, with a leading position in the research and development pipeline, particularly in products like pre-filled methotrexate injection [2] - The product lineup includes potassium chloride sustained-release tablets and various formulations of potassium chloride, achieving a multi-formulation product combination [2] Group 2: Research and Development - The company’s project initiation standards are based on core therapeutic areas and existing production capacity, focusing on products with fewer applications and technical barriers to ensure competitive advantages [3] - R&D costs for generic drugs are generally lower than those for original drugs, influenced by the complexity of development [3] Group 3: Market and Sales - The company has one product, Luguapeptide injection, with annual revenue exceeding 5,000,000 that is not included in the medical insurance list, maintaining stable market share [3] - Sales are primarily through hospitals, with potassium chloride sustained-release tablets also sold in retail pharmacies and e-commerce platforms, although the latter accounts for a smaller share [3] Group 4: Product Expansion and Future Plans - The company is exploring further expansion in traditional Chinese medicine (TCM) products, with a dedicated business development team researching compatible products [4] - The product Pemabertan tablets are expected to be launched in the following year [4] Group 5: Financial and Shareholder Information - The company has not distributed dividends due to negative retained earnings and has implemented a share buyback plan, utilizing 8,000,000 yuan to repurchase 3,230.72 million shares, representing 1.42% of total share capital [5] - The company is currently without a controlling shareholder due to the bankruptcy of the previous major shareholder, with shares auctioned off in November 2025 [5]

金山矿业选矿厂技改完成后，银、金回收率有所提高，选矿成 本有所降低。金山矿业生产能力将逐渐递增至采矿许可证核准的生 产规模 48 万吨/年，并将进一步根据资源情况申请扩大生产规模。 证券代码：000603 证券简称：盛达资源 盛达金属资源股份有限公司投资者关系活动记录表 编号：2025-013 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 活动参与人员 | 线上会议：Fidelity International（Anthony Srom、Lynda Zhou、Luke | | | Li） | | | 现场调研：华福证券（骆奕诚）、和聚投资（陈小鹭） | | 时间 | 2025 年 12 月 23 日 | | 地点 | Zoom、公司会议室 | | 形式 | 线上会议、现场会议 | | 上市公司接待 | 董事会秘书 王薇 | | 人员姓名 | 证券事务代表 孙梦瀛 | | | 投资者关系经理 丛鹏 问：银都矿业的未来展望？ | | | 银都矿业 ...

证券代码：301468 证券简称：博盈特焊 编号：2025-041 广东博盈特焊技术股份有限公司投资者关系活动记录表 | ☑ | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | ☑ | 现场参观 □其他 | | | □线上调研 | | 参与单位名称及 | 中信建投 陈宣霖 屈文敏 | | 人员姓名 | 易方达 倪春尧 | | | 新世界金控 潘煜天 | | 时间 | 年 月 日 2025 12 23 | | 地点 | 广东博盈特焊技术股份有限公司会议室 | | 上市公司接待人 | 1、董事、副总经理、董事会秘书 刘一宁 | | 员姓名 | 2、投资者关系管理专员 谭静怡 一、董事会秘书刘一宁先生简单介绍公司情况 | | | 公司以防腐防磨堆焊装备为核心，长期专注于特种装备制 | | | 造，不断向工业设备整体制造、高端结构件制造及其他大型装备 | | | 制造等方向延伸与拓展。公司的产品和技术主要应用于节能环 | | | 保、电力、能源、化工、冶金、造纸等工业领域。 | | | 公司的竞争能力主要 ...

Group 1: Innovative Drug Development - The company focuses on independent research and development, integrating internal and external resources to address unmet clinical needs, particularly in metabolic and respiratory diseases [1] - As of now, two innovative drug projects have been approved for market, with several others in clinical trial stages [1] - ZSP1601, an innovative drug for treating metabolic dysfunction-related fatty liver disease (MASH), has shown significant efficacy in reducing liver inflammation markers in clinical trials [2] Group 2: Clinical Trials and Results - RAY1225 injection, a dual agonist for GLP-1 and GIP receptors, is currently undergoing multiple Phase III clinical trials for obesity and type 2 diabetes, with positive results reported in Phase II trials [2][12] - The company is advancing RAY1225's clinical trials for treating MASH, with the drug showing potential in improving liver conditions in animal models [13][15] - The company is also conducting Phase III trials for the innovative drug Anlavi (昂拉地韦) for treating influenza, with successful results in previous phases [3][5] Group 3: Market Access and Insurance Inclusion - Anlavi has been included in the 2025 National Medical Insurance Directory, enhancing patient access to this innovative treatment [7][9] - The company’s core products, including Lai Rui Te Wei (来瑞特韦) and other formulations, continue to be part of the updated medical insurance directory, ensuring broader patient coverage [9] Group 4: Future Directions and Research Focus - The company is exploring new drug development avenues in metabolic diseases, focusing on multi-target therapies and long-acting formulations [6] - There is a strategic emphasis on addressing unmet clinical needs in respiratory diseases, particularly with new antiviral agents targeting RSV [5][6]

广州广合科技股份有限公司 证券代码：001389 证券简称：广合科技 广州广合科技股份有限公司投资者关系活动记录表 编号：2025-07 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他 （投资者走进上市公司活动） | | | 2025 年 12 月 11 日：金鹰基金 2025 年 12 月 15 日：IDG | | | 2025 年 12 月 16 日：高盛 | | | 2025 年 12 月 19 日：华安电子、东方红基金、景顺长城 | | 参与单位名称及人 | 基金、永赢基金、华源电子 | | 员姓名（排名不分先 | 2025 年 12 月 22 日： | | | 凯基证券、UG Investment Advisers LTD、南山人寿、 | | 后） | 富兰克林华美投信、丰利资本、国泰证券投资信托、佐佑 | | | 投资、第一金证券自营 | | | 2025 年 12 月 23 日： | | | 全景网、湘财证券及个人投资者（投资者走进上市公 ...